Dual-Band Selective Light Attenuation: Engineering Principles Behind NeuroCalm FLX+ Patented Technology

This technical report presents the engineering principles behind NeuroCalm FLX+ (Indian Patent IN 202521094370, all 10 claims granted), a dual-band selective light attenuation technology for photobiological eyewear. Traditional FL-41 filters attenuate a single broad band between 480-520nm. NeuroCalm FLX+ introduces a dual-band approach, simultaneously filtering 460-490nm (melanopsin/ipRGC-driven pain pathway) and 585-600nm (cone-driven pain pathway) while preserving the 520-560nm green band associated with reduced migraine pain intensity (Noseda et al., 2016). This report examines the limitations of single-band FL-41, the neurobiological evidence for secondary pain wavelengths, the optical engineering challenges of non-contiguous spectral filtration, and the clinical implications of the dual-band approach. Patent claims overview included for transparency.